1. Home
  2. CUE vs GDO Comparison

CUE vs GDO Comparison

Compare CUE & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • GDO
  • Stock Information
  • Founded
  • CUE 2014
  • GDO 2009
  • Country
  • CUE United States
  • GDO United States
  • Employees
  • CUE N/A
  • GDO N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • GDO Finance Companies
  • Sector
  • CUE Health Care
  • GDO Finance
  • Exchange
  • CUE Nasdaq
  • GDO Nasdaq
  • Market Cap
  • CUE 91.9M
  • GDO 84.5M
  • IPO Year
  • CUE 2018
  • GDO N/A
  • Fundamental
  • Price
  • CUE $1.28
  • GDO $11.40
  • Analyst Decision
  • CUE Strong Buy
  • GDO
  • Analyst Count
  • CUE 5
  • GDO 0
  • Target Price
  • CUE $5.00
  • GDO N/A
  • AVG Volume (30 Days)
  • CUE 283.2K
  • GDO 39.4K
  • Earning Date
  • CUE 03-10-2025
  • GDO 01-01-0001
  • Dividend Yield
  • CUE N/A
  • GDO 9.81%
  • EPS Growth
  • CUE N/A
  • GDO N/A
  • EPS
  • CUE N/A
  • GDO N/A
  • Revenue
  • CUE $9,532,000.00
  • GDO N/A
  • Revenue This Year
  • CUE $73.11
  • GDO N/A
  • Revenue Next Year
  • CUE $11.02
  • GDO N/A
  • P/E Ratio
  • CUE N/A
  • GDO N/A
  • Revenue Growth
  • CUE 149.53
  • GDO N/A
  • 52 Week Low
  • CUE $0.45
  • GDO $11.21
  • 52 Week High
  • CUE $2.58
  • GDO $13.04
  • Technical
  • Relative Strength Index (RSI)
  • CUE 46.30
  • GDO 61.66
  • Support Level
  • CUE $1.20
  • GDO $11.20
  • Resistance Level
  • CUE $1.50
  • GDO $11.29
  • Average True Range (ATR)
  • CUE 0.12
  • GDO 0.07
  • MACD
  • CUE -0.02
  • GDO 0.03
  • Stochastic Oscillator
  • CUE 38.30
  • GDO 100.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.

Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.

Share on Social Networks: